Pharmacophore modeling for antitargets

Current Topics in Medicinal Chemistry

Volumn 13, Issue 9, 2013, Pages 1002-1014

  Thai, Khac Minh ^a   Ngo, Trieu Du ^a   Tran, Thanh Dao ^a   Le, Minh Tri ^a  

^a UNIVERSITY OF MEDICINE AND PHARMACY AT HO CHI MINH CITY   (Viet Nam)

Author keywords

ABCB1; Antitargets; Cytochrome P450; hERG; Human ether a go go related gene; P glycoprotein; P gp; Pharmacophore modeling; Pregnane X receptor

Indexed keywords

ABC TRANSPORTER; CYTOCHROME P450; CYTOCHROME P450 26A1; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A; CYTOCHROME P450 3A4; FORMESTANE; KETOCONAZOLE; LASOFOXIFENE; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; PAROXETINE; POTASSIUM CHANNEL HERG; PREGNANE X RECEPTOR; TAMOXIFEN;

BREAST CANCER; CATALYST; DNA FINGERPRINTING; DRUG DESIGN; DRUG SAFETY; HUMAN; HYDROPHOBICITY; LONG QT SYNDROME; MULTIDRUG RESISTANCE; PHARMACOPHORE; PROCESS OPTIMIZATION; REVIEW; RISK ASSESSMENT; STRUCTURE ACTIVITY RELATION; TREATMENT OUTCOME;

ANIMALS; CYTOCHROME P-450 ENZYME SYSTEM; DRUG DISCOVERY; ETHER-A-GO-GO POTASSIUM CHANNELS; HUMANS; MODELS, MOLECULAR; P-GLYCOPROTEIN; RECEPTORS, STEROID;

EID: 84878791324     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/1568026611313090004     Document Type: Review

References (114)

1. Janecek, A.; Demel, M.A.; Thai, K.M.; Ecker, G.F.; Gansterer, W. Predictive QSAR models for polyspecific drug targets: the importance of feature selection Curr. Comput. Aided Drug Des., 2008, 4(2), 91-110.
2. Ecker, G.F.; Stockner, T.; Chiba, P. Computational models forprediction of interactions with ABC-transporter. Drug Discov. Today., 2008, 13, 311-317.
3. Ecker, G.F. In silico screening of promiscuous targets and antitargets. Chemistry Today, 2005, 23, 39-42.
4. Langer, T. Pharmacophores in drug research. Mol. Inf., 2010, 29(6-7), 470-475.
5. Wermuth, C.G.; Ganellin, C.R.; Lindberg, P.; Mitscher, L.A. PureApplied Chem., 1998; Vol. 70, pp. 1129-1143.
6. Löwer, M.; Proschak, E. Structure-based pharmacophores for virtual screening. Mol. Inf., 2011, 30(5), 398-404.
7. Ambudkar, S.V.; Dey, S.; Hrycyna, C.A.; Ramachandra, M.; Pastan, I.; Gottesman, M.M. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu. Rev. Pharmacol. Toxicol., 1999, 39, 361-398.
8. Wandel, C.; Kim, R.B.; Kajiji, S.; Guengerich, P.; Wilkinson, G.R.; Wood, A.J. P-glycoprotein and cytochrome P-450 3A inhibition: dissociation of inhibitory potencies. Cancer Res., 1999, 59(16), 3944-3948.
9. Chan, L.M.; Lowes, S.; Hirst, B.H. The ABCs of drug transport inintestine and liver: efflux proteins limiting drug absorption and bioavailability. Eur. J. Pharm. Sci., 2004, 21(1), 25-51.
10. Gottesman, M.M.; Fojo, T.; Bates, S.E. Multidrug resistance incancer: role of ATP-dependent transporters. Nat. Rev. Cancer, 2002, 2(1), 48-58.
11. Cascorbi, I. Drug interactions-principles, examples and clinicalconsequences. Medicine, 2012, 109(33/34), 546-555.
12. Aller, S.G.; Yu, J.; Ward, A.; Weng, Y.; Chittaboina, S.; Zhuo, R.; Harrell, P.M.; Trinh, Y.T.; Zhang, Q.; Urbatsch, I.L.; Chang, G. Structure of P-glycoprotein reveals a molecular basis for polyspecific drug binding. Science, 2009, 323(5922), 1718-1722.
13. Pajeva, I.K.; Wiese, M. Pharmacophore model of drugs involved inP-glycoprotein multidrug resistance: explanation of structural variety (hypothesis). J. Med. Chem., 2002, 45(26), 5671-5686.
14. Pajeva, I.; Globisch, C.; Fleischer, R.; Tsakovska, I.; Wiese, M. Molecular Modeling of P-Glycoprotein and Related Drugs. Med. Chem. Res., 2005, 14(2), 106-117.
15. Ekins, S.; Kim, R.B.; Leake, B.F.; Dantzig, A.H.; Schuetz, E.G.; Lan, L.B.; Yasuda, K.; Shepard, R.L.; Winter, M.A.; Schuetz, J.D.; Wikel, J.H.; Wrighton, S.A. Three-dimensional quantitative structure-activity relationships of inhibitors of P-glycoprotein. Mol. Pharmacol., 2002, 61(5), 964-973.
16. Ekins, S.; Kim, R.B.; Leake, B.F.; Dantzig, A.H.; Schuetz, E.G.; Lan, L.B.; Yasuda, K.; Shepard, R.L.; Winter, M.A.; Schuetz, J.D.; Wikel, J.H.; Wrighton, S.A. Application of three-dimensional quantitative structure-activity relationships of P-glycoprotein inhibitors and substrates. Mol. Pharmacol., 2002, 61(5), 974-981.
17. Garrigues, A.; Loiseau, N.; Delaforge, M.; Ferte, J.; Garrigos, M.; Andre, F.; Orlowski, S. Characterization of two pharmacophores on the multidrug transporter P-glycoprotein. Mol. Pharmacol., 2002, 62(6), 1288-1298.
18. Langer, T.; Eder, M.; Hoffmann, R.D.; Chiba, P.; Ecker, G.F. Leadidentification for modulators of multidrug resistance based on in silico screening with a pharmacophoric feature model. Arch. Pharm., 2004, 337(6), 317-327.
19. Chang, C.; Bahadduri, P.M.; Polli, J.E.; Swaan, P.W.; Ekins, S.Rapid identification of P-glycoprotein substrates and inhibitors. Drug Metab. Dispos., 2006, 34(12), 1976-1984.
20. Zhou, H.; Wu, S.; Zhai, S.; Liu, A.; Sun, Y.; Li, R.; Zhang, Y.; Ekins, S.; Swaan, P.W.; Fang, B.; Zhang, B.; Yan, B. Design, synthesis, cytoselective toxicity, structure-activity relationships, and pharmacophore of thiazolidinone derivatives targeting drugresistant lung cancer cells. J. Med. Chem., 2008, 51(5), 1242-1251.
21. Palmeira, A.; Rodrigues, F.; Sousa, E.; Pinto, M.; Vasconcelos, M.; Fernandes, M. Pharmacophore-based screening as a clue for the discovery of new p-glycoprotein inhibitors. In: Rocha, M.; Riverola, F.; Shatkay, H.; Corchado, J., Eds.; Advances in Bioinformatics, Berlin: Springer Berlin/Heidelberg, 2010; Vol. 74, pp. 175-180.
22. Rowe, A.; Narlawar, R.; Groundwater, P.W.; Ramzan, I. Kavalac-tone pharmacophores for major cellular drug targets. Mini Rev. Med. Chem., 2011, 11(1), 79-83.
23. Lovekamp, T.; Cooper, P.S.; Hardison, J.; Bryant, S.D.; Guerrini, R.; Balboni, G.; Salvadori, S.; Lazarus, L.H. Inhibition of human multidrug resistance P-glycoprotein 1 by analogues of a potent delta-opioid antagonist. Brain Res., 2001, 902(1), 131-134.
24. Ambo, A.; Ohkatsu, H.; Minamizawa, M.; Watanabe, H.; Suga-wara, S.; Nitta, K.; Tsuda, Y.; Okada, Y.; Sasaki, Y. Relationship between structure and P-glycoprotein inhibitory activity of dimeric peptides related to the Dmt-Tic pharmacophore. Bioorg. Med. Chem. Lett., 2012, 22(6), 2192-2194.
25. M.K. A novel approach using pharmacophore ensem-ble/support vector machine (PhE/SVM) for prediction of hERG liability. Chem. Res. Toxicol., 2007, 20(2), 217-226.
26. Leong, M.K.; Chen, H.B.; Shih, Y.H. Prediction of Promiscuous P-Glycoprotein Inhibition Using a Novel Machine Learning Scheme. Plos One, 2012, 7(3), e33829.
27. Chen, C.N.; Shih, Y.H.; Ding, Y.L.; Leong, M.K. Predicting activation of the promiscuous human pregnane X receptor by pharmacophore ensemble/support vector machine approach. Chem. Res. Toxicol., 2011, 24(10), 1765-1778.
28. Colabufo, N.A.; Berardi, F.; Cantore, M.; Contino, M.; Inglese, C.; Niso, M.; Perrone, R. Perspective of P-glycoprotein modulating agents in oncology and neurodegenerative diseases: pharmaceutical, biological, and diagnostic potentials. J. Med. Chem., 2010, 53(5), 1883-1897.
29. Colabufo, N.A.; Berardi, F.; Perrone, M.G.; Capparelli, E.; Canto-re, M.; Inglese, C.; Perrone, R. Substrates, inhibitors and activators of P-glycoprotein: candidates for radiolabeling and imaging perspectives. Curr. Top. Med. Chem., 2010, 10(17), 1703-1714.
30. Jain, S.; Abraham, I.; Carvalho, P.; Kuang, Y.H.; Shaala, L.A.; Youssef, D.T.; Avery, M.A.; Chen, Z.S.; El Sayed, K.A. Sipholane triterpenoids: chemistry, reversal of ABCB1/P-glycoproteinmediated multidrug resistance, and pharmacophore modeling. J. Nat. Prod., 2009, 72(7), 1291-1298.
31. Ferreira, R.J.; dos Santos, D.J.; Ferreira, M.J.; Guedes, R.C. To-ward a better pharmacophore description of P-glycoprotein modulators, based on macrocyclic diterpenes from Euphorbia species. J. Chem. Inf. Model., 2011, 51(6), 1315-1324.
32. Reis, M.; Ferreira, R.J.; Serly, J.; Duarte, N.; Madureira, A.M.; Santos, D.J.; Molnar, J.; Ferreira, M.J. Colon adenocarcinoma multidrug resistance reverted by Euphorbia diterpenes: structureactivity relationships and pharmacophore modeling. Anticancer Agents Med. Chem., 2012, 12(9), 1015-1024.
33. Choi, C.H. ABC transporters as multidrug resistance mechanismsand the development of chemosensitizers for their reversal. Cancer Cell Int., 2005, 5, 30.
34. Penzotti, J.E.; Lamb, M.L.; Evensen, E.; Grootenhuis, P.D. A computational ensemble pharmacophore model for identifying substrates of P-glycoprotein. J. Med. Chem., 2002, 45(9), 1737-1740.
35. Li, W.X.; Li, L.; Eksterowicz, J.; Ling, X.B.; Cardozo, M. Significance analysis and multiple pharmacophore models for differentiating P-glycoprotein substrates. J. Chem. Inf. Model., 2007, 47(6), 2429-2438.
36. Hall, M.D.; Salam, N.K.; Hellawell, J.L.; Fales, H.M.; Kensler, C.B.; Ludwig, J.A.; Szakacs, G.; Hibbs, D.E.; Gottesman, M.M. Synthesis, activity, and pharmacophore development for isatinbeta-thiosemicarbazones with selective activity toward multidrugresistant cells. J. Med. Chem., 2009, 52(10), 3191-3204.
37. Clancy, C.E.; Kurokawa, J.; Tateyama, M.; Wehrens, X.H.; Kass, R.S. K+ channel structure-activity relationships and mechanisms of drug-induced QT prolongation. Annu. Rev. Pharmacol. Toxicol., 2003, 43, 441-461.
38. Thomas, D.; Karle, C.A.; Kiehn, J. The cardiac hERG/IKr potas-sium channel as pharmacological target: structure, function, regulation, and clinical applications. Curr. Pharm. Des., 2006, 12(18), 2271-2283.
39. Ekins, S. Predicting undesirable drug interactions with promiscu-ous proteins in silico. Drug Discov. Today, 2004, 9(6), 276-285.
40. Hoffmann, P.; Warner, B. Are hERG channel inhibition and QTinterval prolongation all there is in drug-induced torsadogenesis? A review of emerging trends. J. Pharmacol. Toxicol. Methods, 2006, 53(2), 87-105.
41. Fermini, B.; Fossa, A.A. The impact of drug-induced QT intervalprolongation on drug discovery and development. Nat. Rev. Drug Discov., 2003, 2(6), 439-447.
42. Vandenberg, J.I.; Walker, B.D.; Campbell, T.J. HERG K+ chan-nels: friend and foe. Trends Pharmacol. Sci., 2001, 22(5), 240-246.
43. Sanguinetti, M.C.; Mitcheson, J.S. Predicting drug-hERG channelinteractions that cause acquired long QT syndrome. Trends Pharmacol. Sci., 2005, 26(3), 119-124.
44. Roepke, T.K.; Abbott, G.W. Pharmacogenetics and cardiac ionchannels. Vascul. Pharmacol., 2006, 44(2), 90-106.
45. Abriel, H.; Schlapfer, J.; Keller, D.I.; Gavillet, B.; Buclin, T.; Biol-laz, J.; Stoller, R.; Kappenberger, L. Molecular and clinical determinants of drug-induced long QT syndrome: an iatrogenic channelopathy. Swiss. Med. Wkly., 2004, 134(47-48), 685-694.
46. Crumb, W.J., Jr.; Ekins, S.; Sarazan, R.D.; Wikel, J.H.; Wrighton, S.A.; Carlson, C.; Beasley, C.M.Jr. Effects of antipsychotic drugs on I(to), I (Na), I (sus), I (K1), and hERG: QT prolongation, structure activity relationship, and network analysis. Pharm. Res., 2006, 23(6), 1133-1143.
47. Sanguinetti, M.C.; Tristani-Firouzi, M. HERG potassium channelsand cardiac arrhythmia. Nature, 2006, 440(7083), 463-469.
48. Jalaie, M.; Holsworth, D.D. QT interval prolongation: And the beatgoes on. Mini Rev. Med. Chem., 2005, 5(12), 1083-1091.
49. + channel blockade: Current knowledge and strategies for the early prediction during drug development. Med. Res. Rev., 2005, 25(2), 133-166.
50. Testai, L.; Bianucci, A.M.; Massarelli, I.; Breschi, M.C.; Martinot-ti, E.; Calderone, V. Torsadogenic cardiotoxicity of antipsychotic drugs: a structural feature, potentially involved in the interaction with cardiac HERG potassium channels. Curr. Med. Chem., 2004, 11(20), 2691-2706.
51. + channel. A model for bad behavior. J. Med. Chem., 2003, 46(11), 2017-2022.
52. Redfern, W.S.; Carlsson, L.; Davis, A.S.; Lynch, W.G.; MacKenzie, I.; Palethorpe, S.; Siegl, P.K.; Strang, I.; Sullivan, A.T.; Wallis, R.; Camm, A.J.; Hammond, T.G. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc. Res., 2003, 58(1), 32-45.
53. Calderone, V.; Testai, L.; Martinotti, E.; Del Tacca, M.; Breschi, M.C. Drug-induced block of cardiac HERG potassium channels and development of torsade de pointes arrhythmias: the case of antipsychotics. J. Pharm. Pharmacol., 2005, 57(2), 151-161.
54. Yap, Y.G.; Camm, A.J. Drug induced QT prolongation and torsa-des de pointes. Heart, 2003, 89(11), 1363-1372.
55. Finlayson, K.; Witchel, H.J.; McCulloch, J.; Sharkey, J. AcquiredQT interval prolongation and HERG: implications for drug discovery and development. Eur. J. Pharmacol., 2004, 500(1-3), 129-142.
56. Crouch, M.A.; Limon, L.; Cassano, A.T. Clinical relevance andmanagement of drug-related QT interval prolongation. Pharmacotherapy, 2003, 23(7), 881-908.
57. Witchel, H.J. The hERG potassium channel as a therapeutic target. Expert Opin. Ther. Targets, 2007, 11(3), 321-336.
58. Soldovieri, M.V.; Miceli, F.; Taglialatela, M. Cardiotoxic effects ofantihistamines: from basics to clinics (and back). Chem. Res. Toxicol., 2008, 21(5), 997-1004.
59. Ekins, S.; Crumb, W.J.; Sarazan, R.D.; Wikel, J.H.; Wrighton, S.A. Three-dimensional quantitative structure-activity relationship for inhibition of human ether-a-go-go-related gene potassium channel.J. Pharmacol. Exp. Ther., 2002, 301(2), 427-434.
60. Morgan, T.K., Jr.; Sullivan, M.E. An overview of class III electro-physiological agents: a new generation of antiarrhythmic therapy. Prog. Med. Chem., 1992, 29, 65-108.
61. Cavalli, A.; Poluzzi, E.; De Ponti, F.; Recanatini, M. Toward aPharmacophore for Drugs Inducing the Long QT Syndrome: Insights from a CoMFA Study of HERG K+ Channel Blockers. J. Med. Chem., 2002, 45(18), 3844-3853.
62. Pearlstein, R.A.; Vaz, R.J.; Kang, J.; Chen, X.L.; Preobrazhenska-ya, M.; Shchekotikhin, A.E.; Korolev, A.M.; Lysenkova, L.N.; Miroshnikova, O.V.; Hendrix, J.; Rampe, D. Characterization of HERG potassium channel inhibition using CoMSiA 3D QSAR and homology modeling approaches. Bioorg. Med. Chem. Lett., 2003, 13(10), 1829-1835.
63. Aronov, A.M.; Goldman, B.B. A model for identifying HERG K+channel blockers. Bioorg. Med. Chem., 2004, 12(9), 2307-2315.
64. Cianchetta, G.; Li, Y.; Kang, J.; Rampe, D.; Fravolini, A.; Crucia-ni, G.; Vaz, R.J. Predictive models for hERG potassium channel blockers. Bioorg. Med. Chem. Lett., 2005, 15(15), 3637-3642.
65. Aronov, A.M. Common pharmacophores for uncharged humanether-a-go-go-related gene (hERG) blockers. J. Med. Chem., 2006, 49(23), 6917-6921.
66. Aronov, A.M. Tuning out of hERG. Curr. Opin. Drug Discov.Devel., 2008, 11(1), 128-135.
67. Schiesaro, A.; Ecker, G.F. In: Ion Channels and Their Inhibitors; Gupta, S.P., Ed.; Springer-Verlag Berlin Heidelberg, 2011; pp. 191-239.
68. Thai, K.M.; Ecker, G.F. Predictive models for hERG channelblockers: Ligand-based and structure-based approaches. Curr. Med. Chem., 2007, 14(28), 3003-3026.
69. Yamakawa, Y.; Furutani, K.; Inanobe, A.; Ohno, Y.; Kurachi, Y. Pharmacophore modeling for hERG channel facilitation. Biochem. Biophys. Res. Com., 2012, 418(1), 161-166.
70. + channel inhibition by combining 3D-QSAR pharmacophore and 2D-QSAR models. J. Mol. Model., 2012, 18(3), 1023-1036.
71. Moorthy, N.S.; Ramos, M.J.; Fernandes, P.A. Structural analysis of2-piperidin-4-yl-actamide derivatives for hERG blocking and MCH R1 antagonistic activities. Curr. Drug Discov. Technol., 2012, 9(1), 25-38.
72. Thai, K.M.; Windisch, A.; Stork, D.; Weinzinger, A.; Schiesaro, A.; Guy, R.H.; Timin, E.N.; Hering, S.; Ecker G.F. The hERG potassium channel and drug trapping: insight from docking studies with propafenone derivatives. Chem Med Chem, 2010, 5(3), 436-442.
73. Watkins, R.E.; Davis-Searles, P.R.; Lambert, M.H.; Redinbo, M.R. Coactivator binding promotes the specific interaction between ligand and the pregnane X receptor. J. Mol. Biol., 2003, 331(4), 815-828.
74. Mankowski, D.C.; Ekins, S. Prediction of human drug metaboliz-ing enzyme induction. Cur. Drug Metab., 2003, 4(5), 381-391.
75. Watkins, R.E.; Wisely, G.B.; Moore, L.B.; Collins, J.L.; Lambert, M.H.; Williams, S.P.; Willson, T.M.; Kliewer, S.A.; Redinbo, M.R. The human nuclear xenobiotic receptor PXR: structural determinants of directed promiscuity. Science, 2001, 292(5525), 2329-2333.
76. Watkins, R.E.; Maglich, J.M.; Moore, L.B.; Wisely, G.B.; Noble, S.M.; Davis-Searles, P.R.; Lambert, M.H.; Kliewer, S.A.; Redinbo, M.R. 2.1 A crystal structure of human PXR in complex with the St. John's wort compound hyperforin. Biochemistry, 2003, 42(6), 1430-1438.
77. Chrencik, J.E.; Orans, J.; Moore, L.B.; Xue, Y.; Peng, L.; Collins, J.L.; Wisely, G.B.; Lambert, M.H.; Kliewer, S.A.; Redinbo, M.R. Structural disorder in the complex of human pregnane X receptor and the macrolide antibiotic rifampicin. Mol. Endocrinol., 2005, 19(5), 1125-1134.
78. Xue, Y.; Chao, E.; Zuercher, W.J.; Willson, T.M.; Collins, J.L.; Redinbo, M.R. Crystal structure of the PXR-T1317 complex provides a scaffold to examine the potential for receptor antagonism. Bioorg. Med. Chem., 2007, 15(5), 2156-2166.
79. Cheng, Y.; Redinbo, M.R. Activation of the human nuclear xeno-biotic receptor PXR by the reverse transcriptase-targeted anti-HIV drug PNU-142721. Protein Sci., 2011, 20(10), 1713-1719.
80. Ekins, S.; Erickson, J.A. A pharmacophore for human pregnane Xreceptor ligands. Drug Metab. Disp., 2002, 30(1), 96-99.
81. Ekins, S.; Chang, C.; Mani, S.; Krasowski, M.D.; Reschly, E.J.; Iyer, M.; Kholodovych, V.; Ai, N.; Welsh, W.J.; Sinz, M.; Swaan, P.W.; Patel, R.; Bachmann, K. Human pregnane X receptor antagonists and agonists define molecular requirements for different binding sites. Mol. Pharmacol., 2007, 72(3), 592-603.
82. Schuster, D.; Langer, T. The identification of ligand featuresessential for PXR activation by pharmacophore modeling. J. Chem. Inf. Model., 2005, 45(2), 431-439.
83. Ekins, S.; Kholodovych, V.; Ai, N.; Sinz, M.; Gal, J.; Gera, L.; Welsh, W.J.; Bachmann, K.; Mani, S. Computational discovery of novel low micromolar human pregnane X receptor antagonists. Mol. Pharmacol., 2008, 74(3), 662-672.
84. Clark, D.E. In silico ADMET tools: the dawn of a new generation? Expert Opin. Drug Discov., 2007, 2(11), 1423-1429.
85. Norinder, U.; Bergstrom, C.A. Prediction of ADMET Properties. ChemMedChem, 2006, 1(9), 920-937.
86. Fura, A. Role of pharmacologically active metabolites in drugdiscovery and development. Drug Discov. Today, 2006, 11(3-4), 133-142.
87. Ouellet, D.; Bramson, C.; Roman, D.; Remmers, A. E.; Randinitis, E.; Milton, A.; Gardner, M. Effects of three cytochrome P450 inhibitors, ketoconazole, fluconazole, and paroxetine, on the pharmacokinetics of lasofoxifene. Br. J. Clin. Pharmacol., 2007, 63(1), 59-66.
88. deGraaf, C.; Vermeulen, N.P.E.; Feenstra, K. A. Cytochrome p450in silico: an integrative modeling approach. J. Med. Chem., 2005, 48(8), 2725-2755.
89. Nelson, D.R.; Koymans, L.; Kamataki, T.; Stegeman, J.J.; Feyere-isen, R.; Waxman, D.J.; Waterman, M.R.; Gotoh, O.; Coon, M.J.; Estabrook, R.W.; Gunsalus, I.C.; Nebert, D.W. P450 superfamily:update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics, 1996, 6(1), 1-42.
90. de Groot, M.J.; Alex, A.A,; Jones, B.C. Development of a com-bined protein and pharmacophore model for cytochrome P450 2C9. J. Med. Chem., 2002, 45(10), 1983-1993.
91. Rendic, S.; Di Carlo, F.J. Human cytochrome P450 enzymes: astatus report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metab. Rev., 1997, 29(1/2), 413-580.
92. Dehal, S.S.; Brodie, A.M.; Kupfer, D. The aromatase inactivator 4-hydroxyandrostenedione (4-OH-A) inhibits tamoxifen metabolism by rat hepatic cytochrome P-450 3A: potential for drug-drug interaction of tamoxifen and 4-OH-A in combined anti-breast cancer therapy. Drug Metab. Dispos., 1999, 27(3), 389-394.
93. Williams, P.A.; Cosme, J.; Ward, A.; Angove, H.C; Vincovic, D.M; Jhoti, H. Crystal structure of human cytochrome P450 2C9 with bound warfarin. Nature, 2003, 424(6947), 464-468.
94. Williams, P.A.; Cosme, J.; Vincovic, D.M.; Ward, A.; Angove, H.C.; Day, P.J.; Vonrhein, C.; Tickle, I.J.; Jhoti, H. Crystal structures of human cytochrome P450 3A4 bound to metyrapone and progesterone. Science, 2004, 305(5684), 683-686.
95. Melet, A.; Marques-Soares, C.; Schoch, G.A.; Macherey, A.C.; Jaouen, M.; Dansette, P.M.; Sari, M.A.; Johnson, E.F.; Mansuy, D. Analysis of human cytochrome P450 2C8 substrate specificity using a substrate pharmacophore and site-directed mutants. Biochemistry, 2004, 43(49), 15379-15392.
96. Egnell, A.C.; Houston, J.B.; Boyer, C.S. Predictive models ofCYP3A4 Heteroactivation: in vitro-in vivo scaling and pharmacophore modeling. J. Pharmacol. Exp. Ther., 2005, 312(3), 926-937.
97. Ulmschneider, S.; Negri, M.; Voets, M.; Hartmann, R.W. Devel-opment and evaluation of a pharmacophore model for inhibitors of aldosterone synthase (CYP11B2). Bioorg. Med. Chem. Lett., 2006, 16(1), 25-30.
98. Schuster, D.; Laggner, C.; Steindl, T.M.; Langer, T. Developmentand validation of an in silico P450 profiler based on pharmacophore models. Curr. Drug Discov. Technol., 2006, 3(1), 1-48.
99. Schuster, D.; Laggner, C.; Steindl, T.M.; Palusczak, A.; Hartmann, R.W.; Langer, T. Pharmacophore Modeling and In Silico Screening for New P450 19 (Aromatase) Inhibitors. J. Chem. Inf. Model., 2006, 46(3), 1301-1311.
100. Sciabola, S.; Morao, I.; de Groot, M.J. Pharmacophoric fingerprintmethod (TOPP) for 3D-QSAR modeling: application to CYP2D6 metabolic stability. J. Chem. Inf. Model., 2007, 47(1), 76-84.
101. Jones, D.R.; Ekins, S.; Li, L.; Hall, S.D. Computational approachesthat predict metabolic intermediate complex formation with CYP3A4 (+b5). Drug Metab. Dispos., 2007, 35(9), 1466-1475.
102. Nagar, S.; Islam, M.A.; Das, S.; Mukherjee, A.; Saha, A. Pharma-cophore mapping of flavone derivatives for aromatase inhibition. Mol. Divers., 2008, 12(1), 65-76.
103. Leong, M.K.; Chen, Y.M.; Chen, H.B.; Chen, P.H. Development ofa new predictive model for interactions with human cytochrome P450 2A6 using pharmacophore ensemble/support vector machine (PhE/SVM) approach. Pharm. Res., 2009, 26(4), 987-1000.
104. Leong, M.K.; Chen, T.H. Prediction of cytochrome P450 2B6-substrate interactions using pharmacophore ensemble/support vector machine (PhE/SVM) approach. Med. Chem., 2008, 4(4), 396-406.
105. Neves, M.A.; Dinis, T.C.; Colombo, G.; Sáe Melo, M.L. An efficient steroid pharmacophore-based strategy to identify new aromatase inhibitors. Eur. J. Med. Chem., 2009, 44(10), 4121-4127.
106. Mo, S.L.; Liu, Y.H.; Duan, W.; Wei, M.Q.; Kanwar, J.R.; Zhou, S.F. Substrate specificity, regulation, and polymorphism of human cytochrome P450 2B6. Curr. Drug Metab., 2009, 10(7),730-753.
107. Mo, S.L.; Zhou, Z.W.; Yang, L.P.; Wei, M.Q.; Zhou, S.F. Newinsights into the structural features and functional relevance of human cytochrome P450 2C9. Part I. Curr. Drug Metab., 2009, 10(10), 1075-1126.
108. McNulty, J.; Nair, J.J.; Singh, M.; Crankshaw, D.J.; Holloway, A.C. Potent and selective inhibition of human cytochrome P450 3A4 by seco-pancratistatin structural analogs. Bioorg. Med. Chem. Lett., 2010, 20(7), 2335-2339.
109. Muftuoglu, Y.; Mustata, G. Pharmacophore modeling strategies forthe development of novel nonsteroidal inhibitors of human aromatase (CYP19). Bioorg. Med. Chem. Lett., 2010, 20(10), 3050-3064.
110. McNulty, J.; Nair, J.J.; Singh, M.; Crankshaw, D.J.; Holloway, A.C.; Bastida, J. Cytochrome P450 3A4 inhibitory activity studieswithin the lycorine series of alkaloids. Nat. Prod. Commun., 2010, 5(8), 1195-1200.
111. Mo, S.L.; Liu, W.F.; Li, C.G.; Luo, H.B.; Li, R.; Zhou, S.F. Pharmacophore, QSAR, and binding mode studies of substrates of hu-man cytochrome P450 2D6 (CYP2D6) using molecular docking and virtual mutations and an application to chinese herbal medicine screening. Curr. Pharm. Biotechnol., 2012, 13(9), 1640-1704.
112. Mo, S.L.; Liu, W.F.; Chen, Y.; Luo, H.B.; Sun, L.B.; Chen, X.W.; Zhou, Z.W.; Sneed, K.B.; Li, C.G.; Du, Y.M.; Liang, J.; Zhou, S.F. Ligand and protein-based modeling studies of the inhibitors of human cytochrome P450 2D6 and a virtual screening for potentialinhibitors from the Chinese herbal medicine, Scutellaria baicalensis (Huangqin,Baikal Skullcap). Comb. Chem. High Throughput Screen, 2012, 15(1), 36-80.
113. Purushottamachar, P.; Patel, J.B.; Gediya, L.K.; Clement, O.O.; Njar, V.C. First chemical feature-based pharmacophore modelingof potent retinoidal retinoic acid metabolism blocking agents (RAMBAs): identification of novel RAMBA scaffolds. Eur. J. Med. Chem., 2012, 47(1), 412-423.
114. Ramesh, M.; Bharatam, P.V. CYP isoform specificity toward drug metabolism: analysis using common feature hypothesis. J. Mol. Model., 2012, 18(2), 709-720.